Figure 5.
The cost-effectiveness acceptability curves of all randomized patients (A).
C, pemetrexed plus cisplatin/carboplatin; CE, cost-effective; NI, nivolumab plus ipilimumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.